Table 1.

Association of CLS-B with demographic and clinical characteristics

TotalCLS-B+ (N = 41)CLS-B (N = 50)
CharacteristicsN (%)N (%)N (%)Pa
AgeMedian (range)69 (36–96)72 (36–91)65.5 (39–96)0.19
BMI (kg/m2)Median (range)29.9 (19.9–50.5)31.6 (23–50.5)28 (19.9–43.2)<0.01
Country of originDominican Republic57 (63%)23 (56%)34 (68%)0.10
Puerto Rican15 (16%)10 (24%)5 (10%)
South American2 (2%)0 (0%)2 (4%)
Mexican2 (2%)2 (5%)0 (0%)
Cuban0 (0%)0 (0%)0 (0%)
Other Hispanic15 (16%)6 (15%)9 (18%)
EducationHigh school31 (34%)14 (34%)17 (34%)0.48
College22 (24%)7 (17%)15 (30%)
Graduate school24 (26%)12 (29%)12 (24%)
EmploymentEmployed18 (20%)7 (17%)11 (22%)0.43
Unemployed25 (27%)10 (24%)15 (30%)
Retired27 (30%)16 (39%)11 (22%)
Homemaker8 (9%)3 (7%)5 (10%)
Income0–$15,00049 (54%)27 (66%)22 (44%)0.30
$15,000+21 (23%)8 (20%)13 (26%)
Post menopauseYes72 (79%)33 (80%)39 (78%)0.80
No19 (21%)8 (20%)11 (22%)
Current smokingYes8 (9%)6 (15%)2 (4%)0.13
No71 (78%)30 (73%)41 (82%)
History of smokingCurrent7 (8%)5 (12%)2 (4%)0.38
Ever11 (12%)5 (12%)6 (12%)
Never52 (57%)22 (54%)30 (60%)
Current alcohol useYes25 (27%)12 (29%)13 (26%)1.00
No55 (60%)25 (61%)30 (60%)
Stage09 (10%)5 (12%)4 (8%)0.48
I36 (40%)15 (37%)21 (42%)
II35 (38%)14 (34%)21 (42%)
III11 (12%)7 (17%)4 (8%)
ERPositive78 (86%)34 (83%)44 (88%)0.53
Negative11 (12%)6 (15%)5 (10%)
PRPositive64 (70%)29 (71%)35 (70%)1.00
Negative25 (27%)11 (27%)14 (28%)
HER2bPositive7 (8%)5 (12%)2 (4%)0.53
Negative42 (46%)17 (41%)25 (50%)
Indeterminate29 (32%)13 (32%)16 (32%)
Not applicable7 (8%)3 (7%)4 (8%)
Neoadjuvant chemotherapyYes15 (16%)11 (27%)4 (8%)0.02
No75 (82%)29 (71%)46 (92%)
Biological markersNNMean (SD)NMean (SD)P
Liver function tests
 ALT (U/L)863920.5 (9.8)4717.5 (9.1)0.14
 AST (U/L)863920.6 (6.4)4719.5 (6.0)0.42
Adipocyte diameter (μm)
 Mean (SD)8940105.6 (14.1)4999.3 (16.9)0.06
 Range59.7–139.859.7–135.2
  • NOTE: For all variables, the number of participants who did not respond to the question were not displayed in this table, therefore the percentages may not add up to 100%.

  • Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ER, estrogen receptor; PR, progesterone receptor.

  • aFisher exact test excluded the “Unknown” category.

  • bPatients with stage 0 breast cancer were considered not applicable for IHC test.